ENTPD1 and neoplasm: Considering the complete NSCLC cohort (ADC and SCC), the Logrank-test identified a significantly prolonged PFS in patients with high CD39 expression in tumor cells (p = 0.0058) and surrounding stroma cells (p = 0.0067).